Free Trial
NASDAQ:SPRO

Spero Therapeutics (SPRO) Stock Price, News & Analysis

Spero Therapeutics logo
$2.96 +0.06 (+1.90%)
As of 11:00 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Spero Therapeutics Stock (NASDAQ:SPRO)

Key Stats

Today's Range
$2.89
$3.00
50-Day Range
$0.58
$3.02
52-Week Range
$0.51
$3.09
Volume
309,206 shs
Average Volume
2.18 million shs
Market Capitalization
$165.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Moderate Buy

Company Overview

Spero Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

SPRO MarketRank™: 

Spero Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 218th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Spero Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Spero Therapeutics has received no research coverage in the past 90 days.

  • Read more about Spero Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Spero Therapeutics are expected to grow in the coming year, from ($1.20) to ($0.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Spero Therapeutics is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Spero Therapeutics is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Spero Therapeutics has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Spero Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.05% of the float of Spero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Spero Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Spero Therapeutics has recently decreased by 53.74%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Spero Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Spero Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.05% of the float of Spero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Spero Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Spero Therapeutics has recently decreased by 53.74%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 2 people have searched for SPRO on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Spero Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.50% of the stock of Spero Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 25.60% of the stock of Spero Therapeutics is held by institutions.

  • Read more about Spero Therapeutics' insider trading history.
Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Headlines

SPRO Stock Analysis - Frequently Asked Questions

Spero Therapeutics' stock was trading at $1.03 at the beginning of the year. Since then, SPRO stock has increased by 185.0% and is now trading at $2.9350.

Spero Therapeutics, Inc. (NASDAQ:SPRO) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.30. The firm had revenue of $5.87 million for the quarter, compared to analyst estimates of $11 million. Spero Therapeutics had a negative net margin of 156.48% and a negative trailing twelve-month return on equity of 123.50%.

Spero Therapeutics (SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Spero Therapeutics' top institutional investors include Capital Asset Advisory Services LLC (0.06%). Insiders that own company stock include Aquilo Capital Management, Llc, Sath Shukla, Esther Rajavelu, Ankit Mahadevia, Kamal Hamed and Timothy Keutzer.
View institutional ownership trends
.

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spero Therapeutics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META), NVIDIA (NVDA), Editas Medicine (EDIT) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
5/13/2025
Today
7/08/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SPRO
Fax
N/A
Employees
150
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+72.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$68.57 million
Net Margins
-156.48%
Pretax Margin
-156.48%

Debt

Sales & Book Value

Annual Sales
$47.98 million
Price / Cash Flow
N/A
Book Value
$0.85 per share
Price / Book
3.41

Miscellaneous

Free Float
52,836,000
Market Cap
$162.14 million
Optionable
Optionable
Beta
1.33

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:SPRO) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners